HC Wainwright Lifts Earnings Estimates for Co-Diagnostics

Co-Diagnostics, Inc. (NASDAQ:CODX) – Stock analysts at HC Wainwright raised their FY2024 earnings estimates for shares of Co-Diagnostics in a report issued on Monday, November 11th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($1.22) per share for the year, up from their previous forecast of ($1.23). HC Wainwright currently has a “Neutral” rating and a $1.50 target price on the stock. The consensus estimate for Co-Diagnostics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Co-Diagnostics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.17) EPS.

Co-Diagnostics Trading Down 3.6 %

Shares of CODX stock opened at $1.06 on Thursday. The firm has a market capitalization of $33.85 million, a PE ratio of -0.77 and a beta of -0.84. The firm has a fifty day simple moving average of $1.23 and a two-hundred day simple moving average of $1.25. Co-Diagnostics has a 12 month low of $1.00 and a 12 month high of $2.23.

Institutional Trading of Co-Diagnostics

An institutional investor recently bought a new position in Co-Diagnostics stock. Koss Olinger Consulting LLC bought a new position in Co-Diagnostics, Inc. (NASDAQ:CODX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 58,887 shares of the company’s stock, valued at approximately $74,000. Koss Olinger Consulting LLC owned approximately 0.19% of Co-Diagnostics at the end of the most recent reporting period. 14.99% of the stock is owned by institutional investors.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.